Abstract
Coccidioides immitis and C. posadasii are the causative agents of coccidioidomycosis (CM) or Valley Fever, endemic to the alkaline deserts of North and South America. Clinical treatment of CM is predominantly limited to the triazole and polyene drug classes. There are limited therapeutic options for the treatment of CM, most commonly requiring prolonged courses of therapy with established antifungal agents such as azoles and Amphotericin B, which often lead to toxicity and drug resistance. Clearly, there is a need to develop novel and better antifungal drugs against CM. This review examines both repurposed and recently discovered compounds in various stages of development for the treatment of CM.
| Original language | English (US) |
|---|---|
| Article number | 875 |
| Journal | Journal of Fungi |
| Volume | 11 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2025 |
| Externally published | Yes |
Keywords
- Coccidioides
- amphotericin B
- antifungal drugs
- coccidioidomycosis
- drug resistance
- fluconazole
- valley fever
ASJC Scopus subject areas
- Ecology, Evolution, Behavior and Systematics
- Plant Science
- Microbiology (medical)
Fingerprint
Dive into the research topics of 'Drug Discovery and Repurposing for Coccidioides: A Systematic Review'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS